Validation of the two-minute step test in obese with comorbibities and morbidly obese patients

Cardiopulmonary fitness assessment is a valuable resource to obtain quantitative indicators of an individual's physical performance. The cardiopulmonary exercise test (CPX), considered the gold standard test for this evaluation, is costly and difficult to be accessed by the general population. In order to make this evaluation more accessible, and to better reflect the performance of daily life activities, alternative tests were proposed. Morbidly obese patients present limitations that impair physical performance assessment and could benefit from a test of shorter duration, provided it is validated. This observational study aimed to validate the two-minute step test (2MST) as a tool to evaluate functional capacity (FC) in obese with comorbidities and morbidly obese patients, compared the 2MST with CPX as a measure of physical performance, and developed a predictive equation to estimate peak oxygen uptake (VO2) in the 2MST. The CPX and the 2MST were performed and metabolic and ventilatory parameters were recorded in 31 obese individuals (BMI>35 kg/m2). Pearson correlation and multiple linear regression analyses were performed to evaluate the peak VO2 best predictors. Bland-Altman analysis was performed to assess the agreement between the two methods. Peak VO2 measured by CPX and 2MST showed a strong correlation (r=0.70, P<0.001) and there was a moderate correlation between peak VO2 of the 2MST and the number of up-and-down step cycles (UDS) (r=0.55; P=0.01). The reference equation obtained was: VO2 (mL·kg-1·min-1) = 13.341 + 0.138 × total UDS - (0.183 × BMI), with an estimated standard error of 1.3 mL·kg-1·min-1. The 2MST is a viable, practical, and easily accessible test for FC. UDS and BMI can predict peak VO2 satisfactorily.

Post-mortem histological pulmonary analysis in patients with HIV/AIDS

OBJECTIVES: Certain aspects of pulmonary pathology observed in autopsies of HIV/AIDS patients are still unknown. This study considers 250 autopsies of HIV/AIDS patients who died of acute respiratory failure and describes the demographic data, etiology, and histological pulmonary findings of the various pathologies. METHODS: The following data were obtained: age, sex, and major associated diseases (found at the autopsy). Pulmonary histopathology was categorized as: diffuse alveolar damage; pulmonary edema; alveolar hemorrhage; and acute interstitial pneumonia. Odds ratio of the HIV/AIDS-associated diseases developing a specific histopathological pattern was determined by logistic regression. RESULTS: A total of 197 men and 53 women were studied. The mean age was 36 years. Bacterial bronchopneumonia was present in 36 percent (91 cases) and Pneumocystis jiroveci pneumonia in 27 percent (68) of patients. Pulmonary histopathology showed acute interstitial pneumonia in 40 percent (99), diffuse alveolar damage in 36 percent (89), pulmonary edema in 13 percent (33), and alveolar hemorrhage in 12 percent (29) of patients. Multivariate analysis showed a significant and positive association between Pneumocystis jiroveci pneumonia and acute interstitial pneumonia (Odds ratio, 4.51; 95 percent CI, 2.46 - 8.24; p < 0.001), severe sepsis and/or septic shock and diffuse alveolar damage (Odds ratio, 3.60; 95 percent CI, 1.78 -7.27; p < 0.001), and cytomegalovirus and acute interstitial pneumonia (Odds ratio, 2.22; 95 percent CI, 1.01 - 4.93; p = 0.05). CONCLUSIONS: This report is the first autopsy study to include demographic data, etiologic diagnosis, and respective histopathological findings in patients with HIV/AIDS and acute respiratory failure. Further studies are necessary to elucidate the complete pulmonary physiopathological mechanism involved with each HIV/AIDS-associated disease.

Isquemia miocárdica silenciosa / Silent myocardial ischemia

A isquemia miocárdica é o evento fisiopatológico final da doença arterial coronária (DAC). Quando desprovida de sintomatologia é denominada "isquemia miocárdica silenciosa", sendo a responsável pela maior parte dos eventos isquêmicos totais. Ainda permanecem incertos os porquês da näo percepçäo dolorosa ("angina") de certos episódios isquêmicos, bem como dos mecanismos fisiopatológicos que as desencadeiam. Claro está, no entanto, que os eventos silenciosos e sintomáticos näo se diferem quanto às alteraçöes miocárdicas estruturais e funcionais. O diagnóstico de isquemia silenciosa se estabelece quando da detecçäo de alteraçöes objetivas e características de dano miocárdico isquêmico. Dentre os métodos se configuram, principalmente, a eletrocardiografia de esforço, a monitorizaçäo eletrocardiográfica ambulatorial, o teste de perfusäo com tálio-201 e o ecocardiograma de esforço. Há outros, porém de menor utilizaçäo. Destaca-se a isquemia silenciosa pela sua importante relaçäo com o prognóstico dos portadores de DAC. Muitos estudos relatam participaçäo significativa daquela nos variados desfechos da DAC (angina, infarto agudo do miocárdio e morte súbita). O enfoque terapêutico varia para cada paciente, podendo iniciar-se com a mudança do estilo de vida (alteraçäo dos fatores de risco). A terapêutica medicamentosa se baseia na utilizaçäo de drogas antiisquêmicas (nitratos, beta-bloqueadores e antagonistas dos canais de cálcio) e antiplaquetários. o tratamento mais agressivo inclui a angioplastia coronária, a colocaçäo de stents e a cirurgia de revascularizaçäo do miocárdio.